RxDoctor Payments Data

Pamela Davies-Jones

Psychiatric/Mental Health · Oklahoma City, OKNPI 1811555154

Payments from drug & device makers

$2,462in general payments, 2019–2025

Across 93 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$822
  • Alkermes, Inc.$364
  • AbbVie$322
  • E.r. Squibb & Sons, L.L.C.$259
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$244
  • Neurocrine Biosciences, Inc.$180
  • plus $271 from 6 others

What the payments were for

  • Food & beverage$2,39697%
  • Education$663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,462 in reported general payments places this provider in the 70th percentile of 231 psychiatric/mental health providers in Oklahoma.

See all psychiatric/mental health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,916
Medicare patients
15
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate16$156,297
Abilify MaintenaAripiprazole27$72,240
Invega SustennaPaliperidone Palmitate25$63,700
Aripiprazole62$2,797
Hydroxyzine Pamoate49$1,860
Hydroxyzine Hcl38$1,251
Olanzapine OdtOlanzapine13$911
Olanzapine50$842
Benztropine Mesylate51$806
Quetiapine Fumarate45$796
Buspirone Hcl44$787
Duloxetine Hcl48$786
Mirtazapine33$758
Haloperidol38$705
Venlafaxine Hcl ErVenlafaxine Hcl23$694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$822$219,99741 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$110$72,24027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 231 psychiatric/mental health providers in Oklahoma.

Other psychiatric/mental health in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →